---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-004634"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T14:44:40.541298+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kala Pharma reports positive safety data in CHASE Phase 2b trial of KPI-012; second cohort initiated

## Summary
- Both patients in open-label first cohort (high dose 3 U/mL QID) completed at least 1 week with no safety issues.
- Second cohort is randomized, double-masked, vehicle-controlled study of ~90 patients testing two doses vs vehicle for 56 days.
- Primary endpoint is complete healing of PCED measured by corneal fluorescein staining.
- Topline safety and efficacy data expected in Q1 2024; positive results could support first pivotal trial for BLA.

## SEC filing metadata
- accession: 0001558370-23-004634
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837023004634/0001558370-23-004634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837023004634/kala-20230327x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-004634
- JSON: https://secwatch.observer/filing/0001558370-23-004634.json
- Plain text: https://secwatch.observer/filing/0001558370-23-004634.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.